Dengue: Clinical Trials

44 trials for Dengue, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 completed. 44 Phase 2, 7 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 244Completed 44
Phase 17Completed 7
Phase 32Completed 2

Follow Dengue: new trials by email Literature Review of Dengue trials Research Report on Dengue

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
TDV, Placebo - Dengue Fever
Phase 2 / Phase 3CompletedTakeda1872025-01-312025-12-30
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg - DENV-3 Controlled Human Infection Model
Phase 2CompletedAbViro LLC852025-01-072026-03-31
Study to Examine the Effects of Oral Fenretinide
ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo - Dengue
Phase 2CompletedIsland Pharmaceuticals152024-09-052025-10-24
Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients
CPLE, Placebo - Dengue Fever
Phase 1 / Phase 2CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh1842024-06-012025-04-25
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
V181, Butantan - DV - Dengue
Phase 2CompletedButantan Institute13642023-02-152025-11-18
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose - Dengue
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)562022-02-032026-11-04
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients
Montelukast, Placebo - Dengue, Dengue With Warning Signs
Phase 2 / Phase 3CompletedPhramongkutklao College of Medicine and Hospital3582021-01-152023-07-18
Metformin in Dengue With Obesity
Metformin - Dengue, Viral Infection
Phase 1 / Phase 2CompletedOxford University Clinical Research Unit, Vietnam1202020-07-272023-08-31
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company1332019-11-062024-07-19
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
TDV - Dengue Fever
Phase 2CompletedTakeda302018-12-282025-09-08
Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan
Tetravalent live attenuated dengue vaccine admixture TV005, Placebo - Dengue
Phase 2CompletedNational Taiwan University Hospital2522018-10-152023-01-18
Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients
Ivermectin - Dengue Hemorrhagic Fever
Phase 2CompletedMahidol University242018-09-042021-02-24
A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan
TV003, Placebo for TV003 - Dengue
Phase 2CompletedMedigen Vaccine Biologics Corp.542017-12-122019-08-14
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company1182016-07-012022-03-24
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
CYD Dengue Vaccine, Placebo (Sodium chloride 0.9%) - Dengue Fever, Dengue Hemorrhagic Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company10502016-05-022022-03-24
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company2512016-04-142022-03-24
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
TV005 vaccine, Placebo - Dengue
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1922016-03-012025-01-17
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. - Dengue
Phase 1 / Phase 2CompletedU.S. Army Medical Research and Development Command1402015-08-012019-09-25
Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) - Dengue Fever
Phase 2CompletedTakeda3512015-06-032019-08-28
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV Placebo - Dengue Fever
Phase 2CompletedTakeda18002014-12-052020-02-24

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Severe Dengue (20)  ·  Virus Diseases (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Obesity (1)  ·  Overweight (1)  ·  Yellow Fever (1)

Broader conditions

Arbovirus Infections (44)  ·  Flaviviridae Infections (44)  ·  Flavivirus Infections (44)  ·  Hemorrhagic Fevers, Viral (44)  ·  Infections (44)  ·  Mosquito-Borne Diseases (44)  ·  RNA Virus Infections (44)  ·  Vector Borne Diseases (44)  ·  Virus Diseases (42)  ·  Blood-Borne Infections (1)  ·  Body Weight (1)  ·  Communicable Diseases (1)  ·  Genital Diseases (1)  ·  HIV Infections (1)

Interventions

Sodium Chloride (6)  ·  ChimeriVax (2)  ·  Dengue Vaccines (2)  ·  Dosage Forms (2)  ·  Vaccines (2)  ·  adacel (2)  ·  23-valent pneumococcal capsular polysaccharide vaccine (1)  ·  Chickenpox Vaccine (1)  ·  Fenretinide (1)  ·  Hepatitis A Vaccines (1)  ·  Ivermectin (1)  ·  Japanese Encephalitis Vaccines (1)  ·  Measles-Mumps-Rubella Vaccine (1)  ·  Metformin (1)  ·  Pneumococcal Vaccines (1)

Sponsors

Sanofi Pasteur, a Sanofi Company (14)  ·  U.S. Army Medical Research and Development Command (7)  ·  Takeda (5)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Sanofi (3)  ·  AbViro LLC (1)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Butantan Institute (1)  ·  GlaxoSmithKline (1)  ·  Island Pharmaceuticals (1)  ·  Mahidol University (1)  ·  Medigen Vaccine Biologics Corp. (1)  ·  National Taiwan University Hospital (1)  ·  Novo Nordisk A/S (1)  ·  Oxford University Clinical Research Unit, Vietnam (1)

Countries

United States (11)  ·  Thailand (9)  ·  Brazil (4)  ·  Philippines (4)  ·  Singapore (4)  ·  Colombia (3)  ·  Mexico (3)  ·  Puerto Rico (3)  ·  Bangladesh (2)  ·  Honduras (2)  ·  Taiwan (2)  ·  Vietnam (2)  ·  Australia (1)  ·  Dominican Republic (1)  ·  India (1)

Top investigators

Veerachai Watanaveeradej, MD (2)  ·  Alberto Santiago-Cornier, MD (1)  ·  Anna Durbin, MD (1)  ·  Anna Quintero, MD (1)  ·  Bert Slade, MD (1)  ·  Beth D. Kirkpatrick, MD (1)  ·  Clemente Diaz-Perez, MD (1)  ·  Domingo Chardon-Feliciano, MD (1)  ·  Evelyn Matta-Fontanet, MD (1)

Results publications

PMID 40099800, PMID 32932330, PMID 16269927, PMID 18337339, PMID 21813857, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23208878, PMID 23540847, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24189367, PMID 24865677, PMID 24877997, PMID 25483647, PMID 26175027, PMID 26214039, PMID 26291554, PMID 27102820, PMID 27509020, PMID 28365225, PMID 29122463, PMID 29897841, PMID 30241510, PMID 30986790, PMID 31464558, PMID 31843269, PMID 32119591, PMID 32197107, PMID 32342848, PMID 32572472, PMID 33083561, PMID 33212067, PMID 33534885, PMID 33626291, PMID 33711074, PMID 33822015, PMID 35078666, PMID 35364022, PMID 37776876, PMID 38306389, PMID 39308445, PMID 39356094, PMID 40591696, PMID 41213642, PMID 41297006, PMID 41722532

NIH funding

2014 (4), 2018 (1)